After consolidate, harga akan turun, sebb overvalue

Boleh rujuk dokumen :

As at 31 March 2026, being the latest practicable date before the date of this announcement ("LPD")

31 March closing price dia 0.245

PENGIRAAN HARGA RUJUKAN TEORETIKAL (TARP) ?
Anggaran harga PHARMA selepas Consolidated ialah RM1.225 sesaham diperoleh melalui pengiraan harga rujukan teoretikal yang dilaraskan.
────────────────────
? FORMULA:
Harga Rujukan = (Harga Pasaran × Jumlah Saham Sedia Ada) ÷ Jumlah Saham Selepas Penyatuan
────────────────────
? DATA PENGIRAAN (LPD):
1️⃣ Harga Penutup: RM0.245
2️⃣ Jumlah Saham Asal: 6,557,025,388 unit
3️⃣ Jumlah Saham Baharu: 1,311,405,077 unit (Nisbah 5:1)
────────────────────
? JALAN PENGIRAAN:
= (RM0.245 × 6,557,025,388) ÷ 1,311,405,077
= RM1.225
────────────────────
? INFO RINGKAS:
Formula ini memastikan Nilai Pasaran (Market Cap) syarikat kekal sama.
Apabila jumlah unit saham dikurangkan mengikut nisbah 5 kepada 1, harga sesaham akan diselaraskan naik bagi mengimbangi pengurangan unit tersebut.

Maybe go down first coz director want to collect back at the cheaper price

sabar, rm3 on track, spenda koyak beli baru..

itu Khairunnisa sudah tertipu dengan operator pharma, itu suruh jual spenda, tengok la spenda sunmed sudah terbang..

ye jual, jgn jual maruah je.. dah 2.250.. dah suruh jual pharma masuk sunmed lagi berbaloi

all in boss

SUNMED next TP is RM3

SUNMED MORE BETTER

I believe Sunway Healthcare Holdings Berhad is a better buy compared to Pharmaniaga Berhad for several reasons.

Firstly, SUNMED operates a private hospital network with strong growth potential, supported by increasing healthcare demand and Malaysia’s ageing population. This gives it a more stable and defensive long-term outlook.

Secondly, SUNMED is entering the market as a fresh IPO with strong investor interest and expansion plans, which could drive future